Publications by authors named "Jolanda Paolini"

Claim this Profile
P
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo, Jolanda Paolini

Future Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo, Jolanda Paolini

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With -Positive Advanced NSCLC.
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, Jianying Zhou, Takashi Seto, Jolanda Paolini

JTO Clin Res Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Jolanda Paolini

J Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J Solomon, Jolanda Paolini

Cancer Res Treat· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Jolanda Paolini

Am J Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Jolanda Paolini

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, Fiona H Blackhall, Daniel B Costa, Jolanda Paolini

J Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.
J Randolph Hecht, Edith P Mitchell, Takayuki Yoshino, Manfred Welslau, Xun Lin, Jolanda Paolini

Cancer Manag Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, Matthew D Galsky, Lance Leopold, Jolanda Paolini

BJU Int· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Jolanda Paolini

N Engl J Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, Stephen J Clarke, Janette L Vardy, Jolanda Paolini

Clin Genitourin Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, Lisa Sengeløv, Fred Saad, Jolanda Paolini

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
John P Crown, Véronique Diéras, Elzbieta Staroslawska, Denise A Yardley, Thomas Bachelot, Jolanda Paolini

J Clin Oncol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Denise A Yardley, E Claire Dees, Stephen D Myers, Sherry Li, Paul Healey, Jolanda Paolini

Breast Cancer Res Treat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Per E Lønning, Jürgen Geisler, Lars E Krag, Bjørn Erikstein, Yngve Bremnes, Jolanda Paolini

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis